A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026)
Dapivirine (DPV), formulated as vaginal ring, demonstrated HIV risk reduction. MTN-026 explored DPV, formulated as rectal gel, for safety, pharmacokinetics (PK), and acceptability. HIV-uninfected men and women aged 18-45 years were enrolled at United States and Thailand sites and randomized 2:1 to receive DPV 0.05% or placebo gel via rectal applicator. A single-dose phase was followed by seven observed daily doses. Plasma and fluid and tissue from both rectum and cervix were collected at baseline and after the final dose over 72 h for PK, ex-vivo HIV-1 biopsy challenge, histology, and flow cytometry. Twenty-eight participants were randomized; 2 terminated early; 9 were female and 19 male; 12 were white, 11 Asian, 4 black, and 1 other race/ethnicity. Mean age was 28.5 and 34.2 years in the DPV and placebo arms, respectively. Thirty adverse events occurred (all Grade 1 or 2, except one unrelated Grade 3) without study arm differences. DPV rectal tissue concentrations [median (interquartile range)] 0.5-1 and 2 h after a single dose were 256 ng/g [below the lower limit of quantification (BLQ)-666] and BLQ (BLQ-600), respectively, then BLQ (BLQ-BLQ) from 24 to 72 h; concentrations following multiple doses were similar. The largest median DPV plasma concentrations were 0.33 ng/mL (0.15-0.48) after one dose and 0.40 (0.33-0.49) after seven doses. The DPV rectal gel was acceptable and without safety concerns. While DPV plasma concentrations were similar to the vaginal ring, rectal tissue concentrations were well below vaginal ring tissue concentrations, suggesting need for reformulation. Clinical trial number: NCT03239483.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:38 |
|---|---|
| Enthalten in: |
AIDS research and human retroviruses - 38(2022), 4 vom: 01. Apr., Seite 257-268 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cranston, Ross D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.04.2022 Date Revised 02.04.2023 published: Print-Electronic ClinicalTrials.gov: NCT03239483 Citation Status MEDLINE |
|---|
| doi: |
10.1089/AID.2021.0071 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330412450 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330412450 | ||
| 003 | DE-627 | ||
| 005 | 20231225211230.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1089/AID.2021.0071 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330412450 | ||
| 035 | |a (NLM)34498980 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cranston, Ross D |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2022 | ||
| 500 | |a Date Revised 02.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03239483 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Dapivirine (DPV), formulated as vaginal ring, demonstrated HIV risk reduction. MTN-026 explored DPV, formulated as rectal gel, for safety, pharmacokinetics (PK), and acceptability. HIV-uninfected men and women aged 18-45 years were enrolled at United States and Thailand sites and randomized 2:1 to receive DPV 0.05% or placebo gel via rectal applicator. A single-dose phase was followed by seven observed daily doses. Plasma and fluid and tissue from both rectum and cervix were collected at baseline and after the final dose over 72 h for PK, ex-vivo HIV-1 biopsy challenge, histology, and flow cytometry. Twenty-eight participants were randomized; 2 terminated early; 9 were female and 19 male; 12 were white, 11 Asian, 4 black, and 1 other race/ethnicity. Mean age was 28.5 and 34.2 years in the DPV and placebo arms, respectively. Thirty adverse events occurred (all Grade 1 or 2, except one unrelated Grade 3) without study arm differences. DPV rectal tissue concentrations [median (interquartile range)] 0.5-1 and 2 h after a single dose were 256 ng/g [below the lower limit of quantification (BLQ)-666] and BLQ (BLQ-600), respectively, then BLQ (BLQ-BLQ) from 24 to 72 h; concentrations following multiple doses were similar. The largest median DPV plasma concentrations were 0.33 ng/mL (0.15-0.48) after one dose and 0.40 (0.33-0.49) after seven doses. The DPV rectal gel was acceptable and without safety concerns. While DPV plasma concentrations were similar to the vaginal ring, rectal tissue concentrations were well below vaginal ring tissue concentrations, suggesting need for reformulation. Clinical trial number: NCT03239483 | ||
| 650 | 4 | |a Clinical Trial, Phase I | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a HIV prevention | |
| 650 | 4 | |a dapivirine | |
| 650 | 4 | |a microbicides | |
| 650 | 4 | |a rectal | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Gels |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Dapivirine |2 NLM | |
| 650 | 7 | |a TCN4MG2VXS |2 NLM | |
| 700 | 1 | |a Brown, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Bauermeister, José |e verfasserin |4 aut | |
| 700 | 1 | |a Dunne, Eileen F |e verfasserin |4 aut | |
| 700 | 1 | |a Hoesley, Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Sherri |e verfasserin |4 aut | |
| 700 | 1 | |a Lucas, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Dominguez-Islas, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Gundacker, Holly |e verfasserin |4 aut | |
| 700 | 1 | |a Peda, Melissa |e verfasserin |4 aut | |
| 700 | 1 | |a Jacobson, Cindy E |e verfasserin |4 aut | |
| 700 | 1 | |a Kramzer, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Devika |e verfasserin |4 aut | |
| 700 | 1 | |a Dezzutti, Charlene S |e verfasserin |4 aut | |
| 700 | 1 | |a Kunjara Na Ayudhya, Ratiya Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Brand, Rhonda M |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Marzinke, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Piper, Jeanna |e verfasserin |4 aut | |
| 700 | 1 | |a Devlin, Bríd |e verfasserin |4 aut | |
| 700 | 1 | |a Nuttall, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a McGowan, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Hendrix, Craig W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t AIDS research and human retroviruses |d 1990 |g 38(2022), 4 vom: 01. Apr., Seite 257-268 |w (DE-627)NLM012611727 |x 1931-8405 |7 nnns |
| 773 | 1 | 8 | |g volume:38 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:257-268 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1089/AID.2021.0071 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 38 |j 2022 |e 4 |b 01 |c 04 |h 257-268 | ||